+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

LAMEA Non-invasive Prenatal Testing (NIPT) Market Size, Share & Industry Trends Analysis Report By Product, By Application, By End User (Diagnostic Laboratories, Hospitals & Clinics), By Technology, By Country and Growth Forecast, 2023 - 2030

  • PDF Icon

    Report

  • October 2023
  • Region: Africa, Middle East
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5935658
The Latin America, Middle East and Africa Non-invasive Prenatal Testing (NIPT) Market would witness market growth of 21.4% CAGR during the forecast period (2023-2030).

This cutting-edge technology allows for ultra-sensitive and accurate analysis of cell-free DNA. It can potentially identify rare genetic mutations and structural chromosomal abnormalities, further increasing the diagnostic power of NIPT. Innovations are being made to enhance the foetal fraction in maternal blood, which can improve the accuracy of NIPT results, especially in cases where the foetal fraction is low. Some researchers are exploring the integration of multinomic profiling, which involves analyzing various molecular markers in maternal blood, such as microRNA, proteins, and DNA. This multi-faceted approach can provide a more comprehensive view of foetal health.

NIPT is used not only for genetic screening but also for the early detection of pregnancy complications like preeclampsia and gestational diabetes. This expanded application can help healthcare providers intervene earlier and improve pregnancy outcomes. Advances in telehealth and remote monitoring technology allow pregnant individuals to undergo NIPT and receive results from the comfort of their homes, reducing the need for in-person appointments. Some researchers are looking into how NIPT may be used to evaluate how environmental and lifestyle factors affect foetal development and reveal how they might affect health consequences.

The Brazilian government has implemented several initiatives and programs to boost healthcare investments and improve the healthcare system in the country. Unified Health System (Sistema Único de Saúde
  • SUS) is Brazil's public healthcare system, providing free healthcare services to all citizens. The government continuously invests in SUS to improve infrastructure, expand healthcare coverage, and increase the availability of essential medicines. Therefore, the increase in healthcare investments across LAMEA region countries poses lucrative prospects for the growth of the regional market.
The Brazil market dominated the LAMEA Non-invasive Prenatal Testing (NIPT) Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $286.5 Million by 2030. The Argentina market is showcasing a CAGR of 22.1% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 21.1% during (2023 - 2030).

Based on Product, the market is segmented into Consumables & Reagents, and Instruments. Based on Application, the market is segmented into Trisomy, Microdeletion Syndrome, and Others. Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics. Based on Technology, the market is segmented into Next Generation Sequencing (NGS), Microarray, Polymerase Chain Reaction (PCR), and Rolling Circular Amplification. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Illumina, Inc., Natera Inc., F. Hoffmann-La Roche Ltd., PerkinElmer, Inc., Laboratory Corporation of America Holdings, Eurofins Scientific SE, Thermo Fisher Scientific, Inc., GE HealthCare Technologies, Inc., Agilent Technologies, Inc., and Pacific Biosciences of California, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Product
  • Consumables & Reagents
  • Instruments
By Application
  • Trisomy
  • Microdeletion Syndrome
  • Others
By End User
  • Diagnostic Laboratories
  • Hospitals & Clinics
By Technology
  • Next Generation Sequencing (NGS)
  • Microarray
  • Polymerase Chain Reaction (PCR)
  • Rolling Circular Amplification
By Country
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Illumina, Inc.
  • Natera Inc.
  • F. Hoffmann-La Roche Ltd.
  • PerkinElmer, Inc.
  • Laboratory Corporation of America Holdings
  • Eurofins Scientific SE
  • Thermo Fisher Scientific, Inc.
  • GE HealthCare Technologies, Inc.
  • Agilent Technologies, Inc.
  • Pacific Biosciences of California, Inc.

Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Non-invasive Prenatal Testing (NIPT) Market, by Product
1.4.2 LAMEA Non-invasive Prenatal Testing (NIPT) Market, by Application
1.4.3 LAMEA Non-invasive Prenatal Testing (NIPT) Market, by End User
1.4.4 LAMEA Non-invasive Prenatal Testing (NIPT) Market, by Technology
1.4.5 LAMEA Non-invasive Prenatal Testing (NIPT) Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. LAMEA Non-invasive Prenatal Testing (NIPT) Market by Product
4.1 LAMEA Consumables & Reagents Market by Country
4.2 LAMEA Instruments Market by Country
Chapter 5. LAMEA Non-invasive Prenatal Testing (NIPT) Market by Application
5.1 LAMEA Trisomy Market by Country
5.2 LAMEA Microdeletion Syndrome Market by Country
5.3 LAMEA Others Market by Country
Chapter 6. LAMEA Non-invasive Prenatal Testing (NIPT) Market by End User
6.1 LAMEA Diagnostic Laboratories Market by Country
6.2 LAMEA Hospitals & Clinics Market by Country
Chapter 7. LAMEA Non-invasive Prenatal Testing (NIPT) Market by Technology
7.1 LAMEA Next Generation Sequencing (NGS) Market by Country
7.2 LAMEA Microarray Market by Country
7.3 LAMEA Polymerase Chain Reaction (PCR) Market by Country
7.4 LAMEA Rolling Circular Amplification Market by Country
Chapter 8. LAMEA Non-invasive Prenatal Testing (NIPT) Market by Country
8.1 Brazil Non-invasive Prenatal Testing (NIPT) Market
8.1.1 Brazil Non-invasive Prenatal Testing (NIPT) Market by Product
8.1.2 Brazil Non-invasive Prenatal Testing (NIPT) Market by Application
8.1.3 Brazil Non-invasive Prenatal Testing (NIPT) Market by End User
8.1.4 Brazil Non-invasive Prenatal Testing (NIPT) Market by Technology
8.2 Argentina Non-invasive Prenatal Testing (NIPT) Market
8.2.1 Argentina Non-invasive Prenatal Testing (NIPT) Market by Product
8.2.2 Argentina Non-invasive Prenatal Testing (NIPT) Market by Application
8.2.3 Argentina Non-invasive Prenatal Testing (NIPT) Market by End User
8.2.4 Argentina Non-invasive Prenatal Testing (NIPT) Market by Technology
8.3 UAE Non-invasive Prenatal Testing (NIPT) Market
8.3.1 UAE Non-invasive Prenatal Testing (NIPT) Market by Product
8.3.2 UAE Non-invasive Prenatal Testing (NIPT) Market by Application
8.3.3 UAE Non-invasive Prenatal Testing (NIPT) Market by End User
8.3.4 UAE Non-invasive Prenatal Testing (NIPT) Market by Technology
8.4 Saudi Arabia Non-invasive Prenatal Testing (NIPT) Market
8.4.1 Saudi Arabia Non-invasive Prenatal Testing (NIPT) Market by Product
8.4.2 Saudi Arabia Non-invasive Prenatal Testing (NIPT) Market by Application
8.4.3 Saudi Arabia Non-invasive Prenatal Testing (NIPT) Market by End User
8.4.4 Saudi Arabia Non-invasive Prenatal Testing (NIPT) Market by Technology
8.5 South Africa Non-invasive Prenatal Testing (NIPT) Market
8.5.1 South Africa Non-invasive Prenatal Testing (NIPT) Market by Product
8.5.2 South Africa Non-invasive Prenatal Testing (NIPT) Market by Application
8.5.3 South Africa Non-invasive Prenatal Testing (NIPT) Market by End User
8.5.4 South Africa Non-invasive Prenatal Testing (NIPT) Market by Technology
8.6 Nigeria Non-invasive Prenatal Testing (NIPT) Market
8.6.1 Nigeria Non-invasive Prenatal Testing (NIPT) Market by Product
8.6.2 Nigeria Non-invasive Prenatal Testing (NIPT) Market by Application
8.6.3 Nigeria Non-invasive Prenatal Testing (NIPT) Market by End User
8.6.4 Nigeria Non-invasive Prenatal Testing (NIPT) Market by Technology
8.7 Rest of LAMEA Non-invasive Prenatal Testing (NIPT) Market
8.7.1 Rest of LAMEA Non-invasive Prenatal Testing (NIPT) Market by Product
8.7.2 Rest of LAMEA Non-invasive Prenatal Testing (NIPT) Market by Application
8.7.3 Rest of LAMEA Non-invasive Prenatal Testing (NIPT) Market by End User
8.7.4 Rest of LAMEA Non-invasive Prenatal Testing (NIPT) Market by Technology
Chapter 9. Company Profiles
9.1 Illumina, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.5.2 Acquisition and Mergers:
9.1.6 SWOT Analysis
9.2 Natera Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 SWOT Analysis
9.3 F. Hoffmann-La Roche Ltd.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 SWOT Analysis
9.4 PerkinElmer, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Acquisition and Mergers:
9.4.6 SWOT Analysis
9.5 Laboratory Corporation of America Holdings
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental Analysis
9.5.4 SWOT Analysis
9.6 Eurofins Scientific SE
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Recent strategies and developments:
9.6.4.1 Product Launches and Product Expansions:
9.6.5 SWOT Analysis
9.7 Thermo Fisher Scientific, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 WOT Analysis
9.8 GE HealthCare Technologies, Inc.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Product Launches and Product Expansions:
9.8.5.2 Acquisition and Mergers:
9.8.6 SWOT Analysis
9.9 Agilent Technologies, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.9.5 SWOT Analysis
9.10. Pacific Biosciences of California, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 Recent strategies and developments:
9.10.5.1 Acquisition and Mergers:
9.10.6 SWOT Analysis

Companies Mentioned

  • Illumina, Inc.
  • Natera Inc.
  • F. Hoffmann-La Roche Ltd.
  • PerkinElmer, Inc.
  • Laboratory Corporation of America Holdings
  • Eurofins Scientific SE
  • Thermo Fisher Scientific, Inc.
  • GE HealthCare Technologies, Inc.
  • Agilent Technologies, Inc.
  • Pacific Biosciences of California, Inc.

Methodology

Loading
LOADING...